6 pharmaceutical companies in the first quarter of 2020 net profit of more than 1 billion yuan

[Dynamic Networkpharmaceutical industry] Up to now, A-share pharmaceutical companies have disclosed one after another in 2020 in the first quarter report cardIt is reported that the first quarter of 2020, Shanghai Pharmaceutical, Kyushu and other four companies of ten billion revenue, Hengrui Medicine, Mindray Medical, east medicine and other six net profit of over 10 billion, I-Biological, Beta Pharma, Aosai Kang and other eight companies gross margin over 90%It is worth mentioning that the first quarter of this year, over half of the companies revenue, net profit double down; net loss of 53 pharmaceutical companies, a year earlier net loss of only 16the first quarter of 2020, net profit of over 10 billion of six pharmaceutical companies including Hengrui Medicine, Mindray Medical, Yunnan Baiyao, Baiyun Mountain, East China Pharmaceutical, Shanghai PharmaceuticalA netHengruiHengrui ranked head position2020 first quarter net profit of 1.315 billion yuan, an increase of 10.30%In addition, Hengrui Medicine's revenue grew 11.28%industry analysts pointed out that Henry growth continues unabated, the overall performance slightly beat market expectationsIt is worth noting that innovative drugs Hengrui Medicine has gradually entered the harvest period, Ka Ruili beads, apatinib, such as pyrrole erlotinib is expected to help expand the indications for Medicare and thickening performanceMindray Mindray Medicalmedicine in the first quarter net profit of up to 1.313 billion yuan, an increase of 30.58%It is reported that from early January to date, Mindray Medical to deliver a total of tens of thousands of medical equipment units, of which more than 80,000 domestic and overseas nearly 5 million unitsMindray Medical-related executives said in an interview that, Mindray product line accounted for in vitro diagnostic device needs a larger proportion suppressed in the first quarter, only breathing machines, monitors and other vital information and support class equipment high demandWith the social order and routine medical hospital gradually restored, the affected ultrasound, in vitro diagnostics business will return to normal Yunnan Baiyao Yunnan Baiyao first quarter of 2002 net profit of 1.282 billion yuan, down 34.48 percent year on year Yunnan Baiyao Ltd, a pharmaceutical manufacturing, drug development, drug distribution services, resource development of traditional Chinese medicine, nutrition, health care, health care and other services New periodic report shows the company's number of shareholders (households) to 67,600, an increase of 11.48 percent over the previous reporting period Baiyun Mountain Baiyun Mountain first quarter net profit of 1.184 billion yuan, down 15.85 percent It is understood that in the reporting period by reducing investment income 73.22% from a year earlier, mainly due to reduced investment income up long-term equity investment of the Company's subsidiaries under the equity method of accounting; pharmaceutical companies due to the December 2019 issue of accounts receivable assets securitization (ABS), the difference between the book value of accounts receivable and the sale price of the reporting period is recognized as the sale of investment losses, resulting in reduction of the project last year Huadong Medicine East China Pharmaceutical quarter net profit of 1.147 billion, an increase of 26.46%, which, in east China and the US subsidiary of the pharmaceutical industry sector net profit 854 million yuan, an increase of 11.14% Huadong Medicine, said the hospital prescription rate and volume during the first quarter dropped significantly affect the company's core product in patients with medication overall demand remained stable in the hospital, grassroots and retail market maintained a good momentum of development performance continued to benefit from solid growth, with plenty of funds on account Huadong Medicine, highlights the anti-risk ability By the end of the first quarter of this year, East China Pharmaceutical monetary funds of up to 2.705 billion yuan, an increase of 48.43% over last year; quarter the company achieved a net operating cash flow of 219 million yuan Also in the first quarter, continued to promote the East China Pharmaceutical R & D, R & D investment continued to increase, research and development expenses during the reporting period was 2.60 billion yuan, up 69.04 percent concern is that a quarter of the US East China Pharmaceutical Medicine business operations to achieve important results, a wholly-owned subsidiary of BT Sinclair will be long-term agent Sculptra (poly-L-lactic acid microspheres) products in Western Europe equity transfer to the Swiss Galderma The transaction can bring to Sinclair about 30.65 million pounds (269 million yuan) gains on disposal of assets (after tax) Huadong Medicine said the transaction will have a positive impact on the financial statements In addition, Sinclair introduced series of high-end Swiss Kylane company MaiLi hyaluronic acid products, is expected to obtain CE certification in Europe this year and be listed in the various countries, the future is expected to become the US medical industry's core product Shanghai Pharmaceutical Shanghai Pharmaceutical in the first quarter net profit of 10.38 billion yuan, down 7.84 percent year on year Shanghai Pharmaceutical said that in the first quarter of 2020, the stage changed the living habits, including a number of people across the country, including Xunyi inquiry, giving the company's main business operations are indirectly brought varying degrees of impact During the reporting period, the Shanghai Pharmaceutical R & D investment 341 million yuan, up 25.93%; consolidated gross profit margin 15.17%, up 1.12 percentage points from a year earlier.